Search Results - "Lunghofer, Paul J"

The fecal microbiome and serum concentrations of indoxyl sulfate and p‐cresol sulfate in cats with chronic kidney disease by Summers, Stacie C., Quimby, Jessica M., Isaiah, Anitha, Suchodolski, Jan S., Lunghofer, Paul J., Gustafson, Daniel L.

“…Background Intestinal dysbiosis has been documented in humans with chronic kidney disease (CKD) and is thought to contribute to production of the uremic toxins…”
Get full text

First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer by Abbott, Joshua M, Zhou, Qiong, Esquer, Hector, Pike, Laura, Broneske, Travis P, Rinaldetti, Sébastien, Abraham, Adedoyin D, Ramirez, Dominique A, Lunghofer, Paul J, Pitts, Todd M, Regan, Daniel P, Tan, Aik Choon, Gustafson, Daniel L, Messersmith, Wells A, LaBarbera, Daniel V

“…Since the discovery of CHD1L in 2008, it has emerged as an oncogene implicated in the pathology and poor prognosis of a variety of cancers, including…”
Get full text

Drug Design Targeting T‑Cell Factor-Driven Epithelial–Mesenchymal Transition as a Therapeutic Strategy for Colorectal Cancer by Abraham, Adedoyin D, Esquer, Hector, Zhou, Qiong, Tomlinson, Nicholas, Hamill, Brayden D, Abbott, Joshua M, Li, Linfeng, Pike, Laura A, Rinaldetti, Sébastien, Ramirez, Dominique A, Lunghofer, Paul J, Gomez, Jose D, Schaack, Jerome, Nemkov, Travis, D’Alessandro, Angelo, Hansen, Kirk C, Gustafson, Daniel L, Messersmith, Wells A, LaBarbera, Daniel V

“…Metastasis is the cause of 90% of mortality in cancer patients. For metastatic colorectal cancer (mCRC), the standard-of-care drug therapies only palliate the…”
Get full text

Neuroprotective efficacy and pharmacokinetic behavior of novel anti-inflammatory para-phenyl substituted diindolylmethanes in a mouse model of Parkinson's disease by De Miranda, Briana R, Miller, James A, Hansen, Ryan J, Lunghofer, Paul J, Safe, Stephen, Gustafson, Daniel L, Colagiovanni, Dorothy, Tjalkens, Ronald B

“…There are currently no registered drugs that slow the progression of neurodegenerative diseases, in part because translation from animal models to the clinic…”
Get more information

Pharmacokinetics of Sustained-Release Analgesics in Mice by Kendall, Lon V, Hansen, Ryan J, Dorsey, Kathryn, Kang, Sooah, Lunghofer, Paul J, Gustafson, Daniel L

“…Buprenorphine and carprofen, 2 of the most commonly used analgesics in mice, must be administered every 8 to 12 h to provide sustained analgesia…”
Get full text

Pilot study of side effects and serum and urine concentrations of amoxicillin–clavulanic acid in azotemic and non-azotemic cats by Benson, Kellyi K, Quimby, Jessica M, Dowers, Kristy L, Sieberg, Liberty G, Daniels, Joshua B, Langston, Catherine E, Lunghofer, Paul J, Gustafson, Daniel L

“…Objectives The aims of this study were to determine the side effect frequency and serum and urine drug concentrations of amoxicillin–clavulanic acid in cats…”
Get full text

Drug exposure and clinical effect of transdermal mirtazapine in healthy young cats: a pilot study by Benson, Kellyi K, Zajic, Lara B, Morgan, Paula K, Brown, Sarah R, Hansen, Ryan J, Lunghofer, Paul J, Wittenburg, Luke A, Gustafson, Daniel L, Quimby, Jessica M

“…Objectives The objective of this study was to measure drug exposure and clinical effects after administration of transdermal mirtazapine (TMZ) in healthy cats…”
Get full text

Comparative pharmacokinetic properties and antitumor activity of the marine HDACi Largazole and Largazole peptide isostere by Pilon, John L., Clausen, Dane J., Hansen, Ryan J., Lunghofer, Paul J., Charles, Brad, Rose, Barbara J., Thamm, Douglas H., Gustafson, Daniel L., Bradner, James E., Williams, Robert M.

“…Purpose Largazole is a potent class I-selective HDACi natural product isolated from the marine cyanobacteria Symploca sp. The purpose of this study was to test…”
Get full text

Pharmacokinetics of orally administered low-dose rapamycin in healthy dogs by Larson, Jeanne C, Allstadt, Sara D, Fan, Timothy M, Khanna, Chand, Lunghofer, Paul J, Hansen, Ryan J, Gustafson, Daniel L, Legendre, Alfred M, Galyon, Gina D, LeBlanc, Amy K, Martin-Jimenez, Tomas

“…OBJECTIVE To determine the pharmacokinetics of orally administered rapamycin in healthy dogs. ANIMALS 5 healthy purpose-bred hounds. PROCEDURES The study…”
Get full text

A Phase I Dose-Finding Study of Silybin Phosphatidylcholine (Milk Thistle) in Patients With Advanced Hepatocellular Carcinoma by Siegel, Abby B., Narayan, Rupa, Rodriguez, Rosa, Goyal, Abhishek, Jacobson, DrPH, Judith S., Kelly, Kara, Ladas, Elena, Lunghofer, Paul J., Hansen, Ryan J., Gustafson, Daniel L., Flaig, Thomas W., Yann Tsai, Wei, Wu, David P. H., Lee, Valerie, Greenlee, Heather

“…Purpose. To determine the maximum tolerated dose per day of silybin phosphatidylcholine (Siliphos) in patients with advanced hepatocellular carcinoma (HCC) and…”
Get full text

Pharmacokinetics and pharmacodynamics of propofol with or without 2% benzyl alcohol following a single induction dose administered intravenously in cats by Griffenhagen, Gregg M, Rezende, Marlis L, Gustafson, Daniel L, Hansen, Ryan J, Lunghofer, Paul J, Mama, Khursheed R

“…To compare the pharmacokinetics and pharmacodynamics of propofol with or without 2% benzyl alcohol administered intravenously (IV) as a single induction dose…”
Get more information

Comparison of the stability and pharmacokinetics in dogs of modified ciclosporin capsules stored at −20°C and room temperature by Bachtel, Jeremy C., Pendergraft, Jennifer S., Rosychuk, Rodney A. W., Gustafson, Daniel L., Hansen, Ryan J., Lunghofer, Paul J.

“…Background Placement of ciclosporin (Atopica®; Novartis Animal Health, Greensboro, NC, USA) capsules in a freezer prior to administration may reduce the…”
Get full text

Pharmacokinetics of orally administered low-dose rapamycin in healthy dogs: A pilot study by Larson, Jeanne C., Allstadt, Sara D., Fan, Timothy M., Khanna, Chand, Lunghofer, Paul J., Hansen, Ryan J., Gustafson, Daniel L., Legendre, Alfred M., Galyon, Gina D., LeBlanc, Amy K., Martin-Jimenez, Tomas

Get full text